Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Wednesday

Ascendis Pharma A/S (NASDAQ:ASND) is projected to announce its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of $0.8940 per share and revenue of $409.37 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The firm had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. On average, analysts expect Ascendis Pharma A/S to post $3.43 EPS for the current fiscal year and $8.90 EPS for the next fiscal year.

Ascendis Pharma A/S Price Performance

Shares of ASND stock opened at $250.17 on Wednesday. The stock has a 50 day moving average of $242.19 and a two-hundred day moving average of $238.35. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a 12 month low of $188.07 and a 12 month high of $282.15. The company has a market capitalization of $15.61 billion, a P/E ratio of 19.41 and a beta of 0.40.

Insider Activity at Ascendis Pharma A/S

In related news, Director Jean-Jacques Bienaimé bought 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the transaction, the director directly owned 2,900 shares of the company’s stock, valued at $714,357. This represents a 222.22% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares in the company, valued at approximately $810,570. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ASND shares. HC Wainwright set a $344.00 price objective on Ascendis Pharma A/S in a research report on Thursday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $300.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, September 25th. Royal Bank Of Canada boosted their price target on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a report on Friday, August 14th. Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Wedbush restated an “outperform” rating and issued a $327.00 price objective on shares of Ascendis Pharma A/S in a research note on Tuesday, September 1st. Nineteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and an average target price of $305.95.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve treatment convenience, maintain controlled drug exposure, and address unmet medical needs.

Its commercial products include SKYTROFA (lonape­gsomatropin-tcgd), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a once-daily therapy for adults with hypoparathyroidism.